FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362520976> ?p ?o ?g. }

• W4362520976 endingPage "127" @default.
• W4362520976 startingPage "121" @default.
• W4362520976 abstract "Abiraterone acetate tablet is an inhibitor of androgen synthesis, primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluated the bioequivalence and pharmacokinetics of the reference and test formulations of abiraterone acetate tablets in healthy Chinese volunteers.A single-center, open, single-dose, randomized, three-period, three-sequence, semi-repeat (only repeated reference formulations), and reference formulation-corrected fasting reference-scaled average bioequivalence test was conducted in 36 healthy volunteers included in this study. Volunteers were randomly assigned to one of three groups in a 1:1:1 ratio. There was a minimum 7-day washout period between each dose. Blood samples were collected at prescribed time intervals, the plasma concentration of abiraterone acetate tablets was determined by liquid chromatography-tandem mass spectrometry, and adverse events were recorded.Under fasting conditions, the maximum plasma concentration (Cmax) was 27.02 ± 14.21 ng/mL, area under the concentration-time curve from time zero to time t (AUCt) was 125.30 ± 82.41 h·ng/mL, and AUC from time zero to infinity (AUC∞) was 133.70 ± 83.99 h·ng/mL. The 90% confidence intervals (CIs) of the geometric mean ratio (GMR) of AUCt and AUC∞ were in the range of 0.8000-1.2500, and the coefficient of variation (CVWR) of Cmax was more than 30%. The Critbound result was - 0.0522, and the GMR was between 0.8000 and 1.2500.Both test and reference formulations of abiraterone acetate tablets were bioequivalent in healthy Chinese subjects under fasting conditions.ClinicalTrials.gov identifier NCT04863105, registered 26 April 2021-retrospectively registered ( https://register.gov/prs/app/action/SelectProtocol?sid=S000ARAA&selectaction=Edit&uid=U00050YQ&ts=2&cx=-vbtjri." @default.
• W4362520976 created "2023-04-06" @default.
• W4362520976 creator A5004735532 @default.
• W4362520976 creator A5005670014 @default.
• W4362520976 creator A5028833857 @default.
• W4362520976 creator A5030210043 @default.
• W4362520976 creator A5034101477 @default.
• W4362520976 creator A5045066040 @default.
• W4362520976 creator A5056705331 @default.
• W4362520976 creator A5061817335 @default.
• W4362520976 creator A5087739419 @default.
• W4362520976 creator A5088543745 @default.
• W4362520976 date "2023-04-03" @default.
• W4362520976 modified "2023-10-18" @default.
• W4362520976 title "Pharmacokinetics and Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, Three-Period, Three-Sequence Crossover Study" @default.
• W4362520976 cites W1963856068 @default.
• W4362520976 cites W1990609319 @default.
• W4362520976 cites W2054498854 @default.
• W4362520976 cites W2125146007 @default.
• W4362520976 cites W2417838781 @default.
• W4362520976 cites W2745354640 @default.
• W4362520976 cites W2783291377 @default.
• W4362520976 cites W2889646458 @default.
• W4362520976 cites W2904202410 @default.
• W4362520976 cites W2937483840 @default.
• W4362520976 cites W3035757680 @default.
• W4362520976 cites W4252724219 @default.
• W4362520976 cites W4291982393 @default.
• W4362520976 doi "https://doi.org/10.1007/s40268-023-00418-6" @default.
• W4362520976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37012461" @default.
• W4362520976 hasPublicationYear "2023" @default.
• W4362520976 type Work @default.
• W4362520976 citedByCount "0" @default.
• W4362520976 crossrefType "journal-article" @default.
• W4362520976 hasAuthorship W4362520976A5004735532 @default.
• W4362520976 hasAuthorship W4362520976A5005670014 @default.
• W4362520976 hasAuthorship W4362520976A5028833857 @default.
• W4362520976 hasAuthorship W4362520976A5030210043 @default.
• W4362520976 hasAuthorship W4362520976A5034101477 @default.
• W4362520976 hasAuthorship W4362520976A5045066040 @default.
• W4362520976 hasAuthorship W4362520976A5056705331 @default.
• W4362520976 hasAuthorship W4362520976A5061817335 @default.
• W4362520976 hasAuthorship W4362520976A5087739419 @default.
• W4362520976 hasAuthorship W4362520976A5088543745 @default.
• W4362520976 hasBestOaLocation W43625209761 @default.
• W4362520976 hasConcept C112705442 @default.
• W4362520976 hasConcept C121608353 @default.
• W4362520976 hasConcept C126322002 @default.
• W4362520976 hasConcept C126894567 @default.
• W4362520976 hasConcept C142724271 @default.
• W4362520976 hasConcept C197934379 @default.
• W4362520976 hasConcept C204787440 @default.
• W4362520976 hasConcept C22979827 @default.
• W4362520976 hasConcept C27081682 @default.
• W4362520976 hasConcept C2775832370 @default.
• W4362520976 hasConcept C2777899217 @default.
• W4362520976 hasConcept C2780192828 @default.
• W4362520976 hasConcept C42404028 @default.
• W4362520976 hasConcept C44249647 @default.
• W4362520976 hasConcept C71924100 @default.
• W4362520976 hasConcept C76318530 @default.
• W4362520976 hasConcept C87813604 @default.
• W4362520976 hasConcept C98274493 @default.
• W4362520976 hasConceptScore W4362520976C112705442 @default.
• W4362520976 hasConceptScore W4362520976C121608353 @default.
• W4362520976 hasConceptScore W4362520976C126322002 @default.
• W4362520976 hasConceptScore W4362520976C126894567 @default.
• W4362520976 hasConceptScore W4362520976C142724271 @default.
• W4362520976 hasConceptScore W4362520976C197934379 @default.
• W4362520976 hasConceptScore W4362520976C204787440 @default.
• W4362520976 hasConceptScore W4362520976C22979827 @default.
• W4362520976 hasConceptScore W4362520976C27081682 @default.
• W4362520976 hasConceptScore W4362520976C2775832370 @default.
• W4362520976 hasConceptScore W4362520976C2777899217 @default.
• W4362520976 hasConceptScore W4362520976C2780192828 @default.
• W4362520976 hasConceptScore W4362520976C42404028 @default.
• W4362520976 hasConceptScore W4362520976C44249647 @default.
• W4362520976 hasConceptScore W4362520976C71924100 @default.
• W4362520976 hasConceptScore W4362520976C76318530 @default.
• W4362520976 hasConceptScore W4362520976C87813604 @default.
• W4362520976 hasConceptScore W4362520976C98274493 @default.
• W4362520976 hasFunder F4320335960 @default.
• W4362520976 hasIssue "2" @default.
• W4362520976 hasLocation W43625209761 @default.
• W4362520976 hasLocation W43625209762 @default.
• W4362520976 hasOpenAccess W4362520976 @default.
• W4362520976 hasPrimaryLocation W43625209761 @default.
• W4362520976 hasRelatedWork W2033685750 @default.
• W4362520976 hasRelatedWork W2053536280 @default.
• W4362520976 hasRelatedWork W2055974197 @default.
• W4362520976 hasRelatedWork W2087796686 @default.
• W4362520976 hasRelatedWork W2091435156 @default.
• W4362520976 hasRelatedWork W2381431760 @default.
• W4362520976 hasRelatedWork W2604757141 @default.
• W4362520976 hasRelatedWork W2913025776 @default.
• W4362520976 hasRelatedWork W3145656073 @default.
• W4362520976 hasRelatedWork W4366603634 @default.
• W4362520976 hasVolume "23" @default.

• next